CNBCLean R·
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Read at CNBC →
Business · 1 sources covering this
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/7deb6f143794950aba65b1177c9364b698cb24d7" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novo Nordisk's raised forecast fails to change the debate over its obesity business"></iframe>
